Do you have Leber’s hereditary optic neuropathy (LHON) that is affecting your eyesight?

Consider participating in the LEROS Study

The LEROS Study will include approximately 250 patients with LHON in approximately 35 study centres, mostly in Europe. This clinical research study will look at an approved medication, called idebenone, to learn more about its long-term safety and effectiveness for the treatment of LHON.

You may be eligible to take part in the LEROS Study if you:
- are at least 12 years of age
- have been diagnosed with LHON, which has affected your eyesight
- have had symptoms of LHON for no more than 5 years
- have never taken idebenone for the treatment of LHON.

All participants in the LEROS Study will receive idebenone for up to 2 years. During your participation, you will need to visit the study centre up to nine times over a period of about 2 years for health and vision tests.

Study medication and study-related examinations will be provided at no cost to you.

For more information, please contact:

University Hospital of Wales, Cardiff (Prof Marcela Votruba)
Manchester Royal Eye Hospital, Manchester (Mr Alec Ansons)
Moorfields Eye Hospital, London (Mr Patrick Yu Wai Man)
Queen’s Hospital, Romford (Mr Ayman Al Khaier)